Journey Medical Reports Pooled Phase 3 Data For Emrosi In Rosacea
(RTTNews) - Journey Medical Corporation (DERM) on Thursday presented pooled Phase 3 data from MVOR-1 and MVOR-2 evaluating DFD-29 (Emrosi) — 40 mg Minocycline Hydrochloride Modified-Release Capsules — for the treatment of inflammatory lesions of rosacea in adults.
In the pooled analysis, 62.7% of patients treated with DFD-29 achieved Investigator's Global Assessment (IGA) treatment success, compared with 39.0% in the Oracea group and 28.2% in the placebo group. The differences were statistically significant, demonstrating Emrosi's superior efficacy in managing inflammatory lesions of rosacea.
The results were presented at the 2025 Fall Clinical Dermatology Conference, held October 23-26 in Las Vegas, Nevada.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.